RESTON, Va.--(BUSINESS WIRE)--The U.S. Air Force Research Laboratory selected Science Applications International Corp. (NYSE: SAIC) to research laser bioeffects, advance vision science, conduct modeling and simulation, and perform safety engineering, awarding the company a $58 million Optical Radiation Bioeffects and Safety contract. The research program will enhance airman combat survivability by enabling U.S. forces to counter optical hazards and threats.
“We need to keep airmen safe and able to perform their missions effectively on a directed energy battlefield,” said Michael LaRouche, executive vice president and general manager of SAIC’s National Security Customer Group. “Having delivered in-house research for the 711 Human Performance Wing - Optical Radiation Bioeffects Branch for the past 26 years, we’re well positioned to deliver next generation solutions in optical warfare.”
Under the 75-month, cost-plus, fixed-fee contract, SAIC’s team will cover wide-ranging research to define thresholds for biological injury and correlate optical exposure with performance. SAIC will also leverage machine learning capabilities from its Solutions and Technology Group as they seek to enhance laser injury assessments.
SAIC is a premier technology integrator solving our nation’s most complex modernization and readiness challenges across the defense, space, federal civilian, and intelligence markets. Our robust portfolio of offerings includes high-end solutions in systems engineering and integration; enterprise IT, including cloud services; cyber; software; advanced analytics and simulation; and training. With an intimate understanding of our customers’ challenges and deep expertise in existing and emerging technologies, we integrate the best components from our own portfolio and our partner ecosystem to rapidly deliver innovative, effective, and efficient solutions.
We are a team of 23,000 strong driven by mission, united purpose, and inspired by opportunity. Headquartered in Reston, Virginia, SAIC has annual revenues of approximately $6.5 billion. For more information, visit saic.com. For ongoing news, please visit our newsroom.
Certain statements in this release contain or are based on “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “guidance,” and similar words or phrases. Forward-looking statements in this release may include, among others, estimates of future revenues, operating income, earnings, earnings per share, charges, total contract value, backlog, outstanding shares and cash flows, as well as statements about future dividends, share repurchases and other capital deployment plans. Such statements are not guarantees of future performance and involve risk, uncertainties and assumptions, and actual results may differ materially from the guidance and other forward-looking statements made in this release as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these material differences include those discussed in the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Legal Proceedings” sections of our Annual Report on Form 10-K, as updated in any subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, which may be viewed or obtained through the Investor Relations section of our website at saic.com or on the SEC’s website at sec.gov. Due to such risks, uncertainties and assumptions you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. SAIC expressly disclaims any duty to update any forward-looking statement provided in this release to reflect subsequent events, actual results or changes in SAIC’s expectations. SAIC also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others.